Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04603326 · ClinicalTrials.gov registry record
FoxBioNet: ECV (Extracellular Vesicle) 004
A clinical trial of Parkinson Disease, sponsored by Michael J. Fox Foundation for Parkinson's Research.
- Completed
- Registry status
- 140
- Enrollment target
- 4
- Study locations
NCT04603326 is a study of Parkinson Disease that has completed, run by Michael J. Fox Foundation for Parkinson's Research. The registered enrollment target is 140 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (97% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT04603326, a study of Parkinson Disease, has completed, sponsored by Michael J. Fox Foundation for Parkinson's Research.
- COMPLETED
- Registry status
- 140 participants
- Enrollment target
- 4
- Study locations
Study Summary
The goal of this study is to identify reliable markers of LRRK2 activity in human CSF.
Conditions Studied
Interventions
- PROCEDURE Lumbar Puncture
Study Locations (4)
Illinois
- Northwestern University - Chicago
New York
- The Trustees of Columbia University - New York
Oregon
- Oregon Health Sciences Univeristy - Portland
Pennsylvania
- The Trustees of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2021-05-06 |
| Est. Completion | 2023-07-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04603326
The ClinicalTrials.gov registry entry for NCT04603326 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (97% lower). The listed sponsor is Michael J. Fox Foundation for Parkinson's Research, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 1 intervention - of which Lumbar Puncture is the first listed.
NCT04603326 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Illinois, New York, Oregon.
Frequently Asked Questions
What is clinical trial NCT04603326 about?
NCT04603326 is a clinical study titled "FoxBioNet: ECV (Extracellular Vesicle) 004". The goal of this study is to identify reliable markers of LRRK2 activity in human CSF.
What is the current status of trial NCT04603326?
This trial is currently completed. The enrollment target is 140 participants. The study started on 2021-05-06. Estimated completion is 2023-07-01.
What conditions does trial NCT04603326 study?
This clinical trial studies the following conditions: Parkinson Disease.
What interventions are being tested in trial NCT04603326?
The interventions under investigation include: Lumbar Puncture (PROCEDURE).
Who is sponsoring clinical trial NCT04603326?
This trial is sponsored by Michael J. Fox Foundation for Parkinson's Research, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04603326 being conducted?
This trial has 4 study locations across Illinois, New York, Oregon, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson's Disease
RECRUITING · NA
-
Colonoscopic Detection of Phosphorylated Alpha-synuclein for Parkinson's Diagnosis
RECRUITING
-
University of Delaware Parkinson's Disease Registry
RECRUITING
-
Neocortical Microarchitecture of Executive Function
RECRUITING · NA
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
-
Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.